Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2022 08:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
September 28, 2022 08:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations

VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
August 11, 2022 15:09 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
June 23, 2022 19:07 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Results from Annual General Meeting

VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
May 26, 2022 08:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
May 11, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
April 27, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...
April 12, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting

VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
March 30, 2022 09:16 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
March 09, 2022 10:56 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...